Voclosporin: A potentially promising therapeutic agent for noninfectious uveitis

Yasir Jamal Sepah, Elizabeth Harlan Michelle, Brandon Metcalf, Afsheen Khwaja, Roomasa Channa, Mohamed Ibrahim, Elham Hatef, Jangwon Heo, Jeong Lee Hee, Zubir Samsuddin Rentiya, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Voclosporin is a novel calcineurin inhibitor that functions by binding cyclophilin, consequently inhibiting calcineurin activity and preventing the transcription of many genes involved in lymphocyte proliferation and cytokine release. Voclosporin has been shown to be effective in a variety of autoimmune diseases, such as rheumatoid arthritis, psoriasis and renal transplant rejection. Noninfectious uveitis is also an immune-mediated disease which, if left untreated, can cause severe loss of vision. Presently, corticosteroids are the mainstay of therapy in noninfectious uveitis. However, there are several metabolic and ophthalmic adverse effects associated with the long-term use of corticosteroids. Voclosporin has recently been shown in the LX-211 Uveitis Multicenter Investigation of a New Approach to Treatment (LUMINATE) clinical trial program to be effective in the treatment of noninfectious uveitis. With an acceptable side-effects profile, voclosporin is an exciting addition to the therapeutic options available in the management of noninfectious uveitis.

Original languageEnglish (US)
Pages (from-to)281-286
Number of pages6
JournalExpert Review of Ophthalmology
Volume6
Issue number3
DOIs
StatePublished - Jun 2011

Keywords

  • LUMINATE
  • autoimmune
  • calcineurin inhibitor
  • uveitis
  • voclosporin

ASJC Scopus subject areas

  • Biomedical Engineering
  • Ophthalmology
  • Optometry

Fingerprint Dive into the research topics of 'Voclosporin: A potentially promising therapeutic agent for noninfectious uveitis'. Together they form a unique fingerprint.

Cite this